HRP20211754T1 - Novi peptidi i kombinacije peptida za upotrebu u imunoterapiji protiv hepatocelularnog karcinoma (hcc) i drugih rakova - Google Patents

Novi peptidi i kombinacije peptida za upotrebu u imunoterapiji protiv hepatocelularnog karcinoma (hcc) i drugih rakova Download PDF

Info

Publication number
HRP20211754T1
HRP20211754T1 HRP20211754TT HRP20211754T HRP20211754T1 HR P20211754 T1 HRP20211754 T1 HR P20211754T1 HR P20211754T T HRP20211754T T HR P20211754TT HR P20211754 T HRP20211754 T HR P20211754T HR P20211754 T1 HRP20211754 T1 HR P20211754T1
Authority
HR
Croatia
Prior art keywords
peptide
cell
expression vector
tcr
nucleic acid
Prior art date
Application number
HRP20211754TT
Other languages
English (en)
Inventor
Toni Weinschenk
Andrea Mahr
Jens Fritsche
Phillip Müller
Anita WIEBE
Sarah MISSEL
Original Assignee
Immatics Biotechnologies Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1501017.6A external-priority patent/GB201501017D0/en
Application filed by Immatics Biotechnologies Gmbh filed Critical Immatics Biotechnologies Gmbh
Publication of HRP20211754T1 publication Critical patent/HRP20211754T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2046—IL-7
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/208—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/00111—Hepatocyte growth factor receptor [HGFR or c-met]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1057—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from liver or pancreas
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)

Claims (15)

1. Peptid koji sadrži aminokiselinsku sekvencu ID BR. SEKV 56 i farmaceutski prihvatljivu sol od nje, pri čemu je navedeni peptid ukupne duljine do 30 aminokiselina i pri čemu navedeni peptid ima sposobnost vezivanja s molekulom glavnog kompleksa gena tkivne podudarnosti (MHC) klase I molekule i ima sposobnost biti prepoznata putem CD8 T stanica kada se veže na MHC.
2. Peptid u skladu s patentnim zahtjevom 1, pri čemu ukupna duljina navedenog peptida iznosi do 16 aminokiselina i po mogućnosti pri čemu se navedeni peptid sastoji od aminokiselinske sekvence prema SEQ ID br. 56.
3. Peptid u skladu s patentnim zahtjevom 1 ili 2, pri čemu navedeni peptid uključuje nepeptidne veze, i/ili pri čemu je navedeni peptid dio fuzioniranog proteina koji sadrži N-terminalne aminokiseline HLA-DR invarijantnog lanca vezanog za antigene (Ii).
4. Antitijelo, topljivo ili koje se vezuje za membranu, koje specifično prepoznaje peptid u skladu s bilo kojim od patentnih zahtjeva 1 do 3, po mogućnosti peptid u skladu s bilo kojim od patentnih zahtjeva 1 do 3 koji se vezuje za MHC molekulu.
5. T-stanični receptor (TCR), topljiv ili koji se vezuje za membranu, koji reagira sa HLA ligandom, pri čemu navedeni ligand ima najmanje 88% sličnosti s, i po mogućnosti se sastoji od aminokiselinske sekvence od ID BR. SEKV 56, pri čemu je opcionalno navedeni TCR dat kao topljiva molekula i nadalje opcionalno nosi daljnju efektorsku funkciju kao što je imunostimulirajuća domena ili toksin.
6. Nukleinska kiselina, koja kodira peptid u skladu s bilo kojim od patentnih zahtjeva od 1 do 3, antitijelo u skladu s patentnim zahtjevom 4, TCR u skladu s patentnim zahtjevom 5, ili ekspresijski vektor koji eksprimira navedenu nukleinsku kiselinu.
7. Stanica domaćina koja sadrži peptid u skladu s bilo kojim od patentnih zahtjeva 1 do 3, ili nukleinsku kiselinu ili ekspresijski vektor u skladu s patentnim zahtjevom 6, pri čemu je navedena stanica domaćin po mogućnosti stanica koja prezentira antigen, kao što je dendritična stanica, ili T stanica ili NK stanica.
8. Metoda za proizvodnju peptida u skladu s bilo kojim od patentnih zahtjeva od 1 do 3, antitijelo u skladu s patentnim zahtjevom 4, ili TCR u skladu s patentnim zahtjevom 5, metoda je koja se sastoji od kultiviranja stanice domaćina u skladu s patentnim zahtjevom 7 koji predstavlja peptid u skladu s bilo kojim od patentnih zahtjeva od 1 do 3, ili eksprimira nukleinsku kiselinu ili ekspresijski vektor u skladu s patentnim zahtjevom 6, i izoliranjem navedenog peptida, navedeno antitijelo ili navedeni TCR iz stanice domaćina i/ili medija za kultiviranje.
9. In vitro metoda za proizvodnju aktiviranih T-limfocita, metoda je koja obuhvaća kontaktiranje in vitro T stanica humanim MHC molekulama klase I s umetnutim antigenima koje se eksprimiraju na površini odgovarajuće stanice koja prezentira antigen ili umjetnog spoja koji oponaša stanicu koja prezentira antigen u vremenskom razdoblju dovoljnom da se aktiviraju navedene T stanice na način svojstven antigenu, pri čemu je navedeni antigen peptid u skladu s patentnim zahtjevom 1 ili 2.
10. Aktivirana T stanica, proizvedena metodom u skladu s patentnim zahtjevom 9, koja selektivno prepoznaje stanicu koja predstavlja polipeptid koji se sastoji od sekvence aminokiselina navedene u patentnom zahtjevu 1 ili 2.
11. Farmaceutska smjesa, koja se sastoji od najmanje jednog aktivnog sastojka odabranog iz grupe koja se sastoji od peptida u skladu s bilo kojim od patentnih zahtjeva od 1 do 3, antitijela u skladu s patentnim zahtjevom 4, TCR u skladu s patentnim zahtjevom 5, nukleinske kiseline ili ekspresijskog vektora u skladu s patentnim zahtjevom 6, stanice domaćina koja se sastoji od ekspresijskog vektora u skladu s patentnim zahtjevom 7, aktivirane T stanice u skladu s patentnim zahtjevom 10, i farmaceutski prihvatljivog nosača, te opcionalno, farmaceutski prihvatljivih pomoćnih supstanci i / ili stabilizatora.
12. Peptid u skladu s bilo kojim od patentnih zahtjeva od 1 do 3, antitijelo u skladu s patentnim zahtjevom 4, TCR u skladu s patentnim zahtjevom 5, nukleinska kiselina ili ekspresijski vektor u skladu s patentnim zahtjevom 6, stanica domaćina koja se sastoji od ekspresijskog vektora u skladu s patentnim zahtjevom 7, aktivirana T stanica u skladu s patentnim zahtjevom 10, ili farmaceutska smjesa u skladu s patentnim zahtjevom 11 za upotrebu u medicini.
13. Peptid u skladu s bilo kojim od patentnih zahtjeva od 1 do 3, antitijelo u skladu s patentnim zahtjevom 4, TCR u skladu s patentnim zahtjevom 5, nukleinska kiselina ili ekspresijski vektor u skladu s patentnim zahtjevom 6, stanica domaćina koja se sastoji od ekspresijskog vektora u skladu s patentnim zahtjevom 7, aktivirana T stanica u skladu s patentnim zahtjevom 10, ili farmaceutska smjesa u skladu s patentnim zahtjevom 11 za upotrebu u liječenju raka.
14. Peptid u skladu s bilo kojim od patentnih zahtjeva od 1 do 3, antitijelo u skladu s patentnim zahtjevom 4, TCR u skladu s patentnim zahtjevom 5, nukleinska kiselina ili ekspresijski vektor u skladu s patentnim zahtjevom 6, stanica domaćina koja se sastoji od ekspresijskog vektora u skladu s patentnim zahtjevom 7, aktivirana T stanica u skladu s patentnim zahtjevom 10, ili farmaceutska smjesa u skladu s patentnim zahtjevom 11 za upotrebu u skladu s patentnim zahtjevom 13, pri čemu je navedeni rak odabran iz grupe HCC, raka mozga, raka bubrega, raka pankreasa, debelog crijeva ili rektalnog raka, ili leukemije i drugih tumora koji pokazuju pretjeranu ekspresiju SLC16A11.
15. Komplet koji se sastoji od: (a) posude koja sadrži farmaceutsku smjesu u skladu s patentnim zahtjevom 11, u otopini ili u liofiliziranom obliku; (b) opcionalno, druge posude koja sadrži otapalo ili otopinu za rekonstituciju za liofiliziranu formulaciju; (c) opcionalno, upute za (i) korištenje otapala ili (ii) rekonstituciju i/ili korištenje liofilizirane formulacije i po potrebi, koja se nadalje sastoji od jednog ili više (iii) pafera, (iv); otapala, (v) filtra, (vi) igle, ili (vii) štrcaljke.
HRP20211754TT 2014-12-23 2015-12-16 Novi peptidi i kombinacije peptida za upotrebu u imunoterapiji protiv hepatocelularnog karcinoma (hcc) i drugih rakova HRP20211754T1 (hr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201462096165P 2014-12-23 2014-12-23
GB201423016 2014-12-23
GBGB1501017.6A GB201501017D0 (en) 2014-12-23 2015-01-21 Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers
EP19199125.6A EP3626731B1 (en) 2014-12-23 2015-12-16 Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (hcc) and other cancers

Publications (1)

Publication Number Publication Date
HRP20211754T1 true HRP20211754T1 (hr) 2022-03-04

Family

ID=66846825

Family Applications (5)

Application Number Title Priority Date Filing Date
HRP20211580TT HRP20211580T1 (hr) 2014-12-23 2015-12-16 Novi peptidi i kombinacije peptida za upotrebu u imunoterpiji protiv hepatocelularnog karcinoma (hcc) i drugih rakova
HRP20211754TT HRP20211754T1 (hr) 2014-12-23 2015-12-16 Novi peptidi i kombinacije peptida za upotrebu u imunoterapiji protiv hepatocelularnog karcinoma (hcc) i drugih rakova
HRP20192212TT HRP20192212T4 (hr) 2014-12-23 2015-12-16 Novi peptidi i kombinacije peptida za upotrebu u imunoterapiji protiv hepatocelularnog karcinoma (hcc) i drugih rakova
HRP20211753TT HRP20211753T1 (hr) 2014-12-23 2015-12-16 Novi peptidi i kombinacije peptida za upotrebu u imunoterapiji protiv hepatocelularnog karcinoma (hcc) i drugih rakova
HRP20211327TT HRP20211327T1 (hr) 2014-12-23 2015-12-16 Novi peptidi i kombinacije peptida za upotrebu u imunoterapiji protiv hepatocelularnog karcinoma (hcc) i drugih rakova

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HRP20211580TT HRP20211580T1 (hr) 2014-12-23 2015-12-16 Novi peptidi i kombinacije peptida za upotrebu u imunoterpiji protiv hepatocelularnog karcinoma (hcc) i drugih rakova

Family Applications After (3)

Application Number Title Priority Date Filing Date
HRP20192212TT HRP20192212T4 (hr) 2014-12-23 2015-12-16 Novi peptidi i kombinacije peptida za upotrebu u imunoterapiji protiv hepatocelularnog karcinoma (hcc) i drugih rakova
HRP20211753TT HRP20211753T1 (hr) 2014-12-23 2015-12-16 Novi peptidi i kombinacije peptida za upotrebu u imunoterapiji protiv hepatocelularnog karcinoma (hcc) i drugih rakova
HRP20211327TT HRP20211327T1 (hr) 2014-12-23 2015-12-16 Novi peptidi i kombinacije peptida za upotrebu u imunoterapiji protiv hepatocelularnog karcinoma (hcc) i drugih rakova

Country Status (28)

Country Link
US (10) US20220016227A1 (hr)
JP (8) JP2020191866A (hr)
KR (4) KR102643923B1 (hr)
AU (1) AU2022268329A1 (hr)
CL (1) CL2021001479A1 (hr)
CO (1) CO2017003772A2 (hr)
CR (1) CR20210289A (hr)
CY (5) CY1122491T1 (hr)
DK (1) DK3236985T4 (hr)
ES (5) ES2887107T3 (hr)
FI (1) FI3236985T4 (hr)
HR (5) HRP20211580T1 (hr)
HU (5) HUE056607T2 (hr)
IL (1) IL281752A (hr)
LT (5) LT3616706T (hr)
MA (6) MA48487B1 (hr)
MD (5) MD3626731T2 (hr)
MX (6) MX2020004757A (hr)
MY (1) MY178137A (hr)
PE (1) PE20211740A1 (hr)
PL (4) PL3616706T3 (hr)
PT (5) PT3626729T (hr)
RS (1) RS62575B1 (hr)
SG (2) SG10202102698VA (hr)
SI (2) SI3626731T1 (hr)
TW (3) TW202321273A (hr)
UA (1) UA124331C2 (hr)
ZA (1) ZA201701762B (hr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3616706T3 (pl) * 2014-12-23 2022-02-07 Immatics Biotechnologies Gmbh Nowe peptydy i kombinacja peptydów do stosowania w immunoterapii względem raka komórek wątroby (HCC) i innych rodzajów raka
CN114720691B (zh) * 2022-05-10 2022-12-09 深圳粒影生物科技有限公司 一种检测生物标志物的试剂盒及其制备方法和应用

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020177551A1 (en) * 2000-05-31 2002-11-28 Terman David S. Compositions and methods for treatment of neoplastic disease
AU2061201A (en) 1999-12-17 2001-06-25 Chiron Corporation Mammalian dishevelled-associated proteins
AU2001232204A1 (en) 2000-02-22 2001-09-03 Ahuva Nissim Chimeric and tcr phage display libraries, chimeric and tcr reagents and methods of use thereof
US20020048550A1 (en) 2000-07-20 2002-04-25 Vallera Daniel A. Radiolabeled immunotoxins
US7919467B2 (en) * 2000-12-04 2011-04-05 Immunotope, Inc. Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
US20050053918A1 (en) * 2001-05-16 2005-03-10 Technion Research & Development Foundation Ltd. Method of identifying peptides capable of binding to MHC molecules, peptides identified thereby and their uses
US6867283B2 (en) * 2001-05-16 2005-03-15 Technion Research & Development Foundation Ltd. Peptides capable of binding to MHC molecules, cells presenting such peptides, and pharmaceutical compositions comprising such peptides and/or cells
US20070134261A1 (en) * 2001-12-03 2007-06-14 Hancock Robert E Effectors of innate immunity
US7311914B2 (en) 2002-08-13 2007-12-25 Ludwig Institute For Cancer Research MAGE-A4 antigenic peptides and uses thereof
US20040091503A1 (en) * 2002-08-20 2004-05-13 Genitrix, Llc Lectin compositions and methods for modulating an immune response to an antigen
JP4406607B2 (ja) 2002-08-26 2010-02-03 オンコセラピー・サイエンス株式会社 ペプチド及びこれを含む医薬
NZ570811A (en) 2002-11-09 2009-11-27 Immunocore Ltd T cell receptor display
US20040096982A1 (en) 2002-11-19 2004-05-20 International Business Machines Corporation Methods and apparatus for analysis of mass spectra
DE602004015064D1 (de) 2003-01-06 2008-08-28 Wyeth Corp Zusammensetzungen und verfahren zur diagnose und behandlung von kolonkrebs
US20090304679A1 (en) * 2004-05-27 2009-12-10 Weidanz Jon A Antibodies as T cell receptor mimics, methods of production and uses thereof
US20090233318A1 (en) 2004-12-28 2009-09-17 Weidanz Jon A Methods of assaying vaccine potency
US20090075304A1 (en) 2004-05-27 2009-03-19 Weidanz Jon A Methods of assaying vaccine potency
DK1806359T3 (da) 2005-09-05 2010-06-14 Immatics Biotechnologies Gmbh Tumorassocierede peptider, der bindes promiskuøst til Humant Leukocyt-Antigen (HLA) klasse II molekyler
DE602005016112D1 (de) 2005-09-05 2009-10-01 Immatics Biotechnologies Gmbh Tumorassoziierte Peptide, die HLA Klasse I oder II-Moleküle binden, und anti-Tumor Impfstoffe
WO2008021290A2 (en) 2006-08-09 2008-02-21 Homestead Clinical Corporation Organ-specific proteins and methods of their use
WO2008156655A2 (en) * 2007-06-15 2008-12-24 Genelux Corporation Vaccinia virus vectors encoding a sodium-dependent transporter protein for imaging and/or treatment of tumors
WO2009026547A1 (en) 2007-08-22 2009-02-26 Receptor Logi, Ltd. Methods of assaying vaccine potency
ES2573458T3 (es) 2007-09-14 2016-06-08 Vrije Universiteit Brussel Mejoramiento de la capacidad estimulatoria de las células T de las células que presentan antígeno humano y su uso en vacunación
EP2262834A4 (en) 2008-02-27 2011-08-17 Receptor Logic Inc ANTIBODIES THAT IMITATE L-CELL RECEPTORS AND METHODS OF MAKING AND USING SAME
WO2009151487A1 (en) 2008-06-13 2009-12-17 Receptor Logic, Inc. Methods of assaying vaccine potency
DE102008049136B4 (de) 2008-09-26 2012-10-25 Leibniz-Institut für Naturstoff-Forschung und Infektionsbiologie e.V. Neue Regulatoren des angeborenen Immunsystems
ES2536465T3 (es) * 2008-10-01 2015-05-25 Immatics Biotechnologies Gmbh Composición de péptidos tumor-asociados y relacionados con la vacuna contra el cáncer para el tratamiento de glioblastoma (GBM) y otros cánceres
WO2010059742A1 (en) * 2008-11-18 2010-05-27 Collabrx, Inc. Individualized cancer treatment
CA2780753A1 (en) 2009-11-14 2011-05-19 Kuang-Yuh Chyu Immunomodulatory methods and systems for treatment and/or prevention of atherosclerosis
US8506964B2 (en) 2010-02-05 2013-08-13 Cardiovax, Llc Fusion proteins and related compositions, methods and systems for treatment and/or prevention of atherosclerosis
CN103501806A (zh) 2010-11-12 2014-01-08 赛达斯西奈医疗中心 用于治疗和/或预防动脉瘤的免疫调节方法和系统
CA2817543A1 (en) 2010-11-12 2012-06-07 Cedars-Sinai Medical Center Immunomodulatory methods and systems for treatment and/or prevention of hypertension
US20130302362A1 (en) * 2010-11-12 2013-11-14 Cedars-Sinai Medical Center Immunomodulatory Compositions, Methods and Systems Comprising Immunogenic Fragments of ApoB-100
JP6415977B2 (ja) * 2011-04-15 2018-10-31 ジェネラックス・コーポレイションＧｅｎｅｌｕｘ Ｃｏｒｐｏｒａｔｉｏｎ 弱毒化ワクシニアウイルスのクローン株およびその使用方法
US9221876B2 (en) * 2011-11-11 2015-12-29 Cardiovax, Llc Methods for treating kidney disease with fragments of ApoB-100
GB201208293D0 (en) 2012-05-11 2012-06-20 Circassia Ltd Hydrochlorice salt of peptide
WO2014039675A2 (en) 2012-09-05 2014-03-13 University Of Virginia Patent Foundation Target peptides for colorectal cancer therapy and diagnostics
GB201301632D0 (en) 2013-01-30 2013-03-13 Imp Innovations Complement System
US9134326B2 (en) 2013-03-14 2015-09-15 Battelle Memorial Institute Biomarkers for liver fibrosis
CN103739667B (zh) 2013-09-24 2017-08-25 上海宇研生物技术有限公司 卵巢癌特异的肿瘤抗原肽及其制备方法
SG11201607181WA (en) 2014-03-14 2016-09-29 Immunocore Ltd Tcr libraries
PL3616706T3 (pl) * 2014-12-23 2022-02-07 Immatics Biotechnologies Gmbh Nowe peptydy i kombinacja peptydów do stosowania w immunoterapii względem raka komórek wątroby (HCC) i innych rodzajów raka
GB201501017D0 (en) 2014-12-23 2015-03-04 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers
GB201507719D0 (en) 2015-05-06 2015-06-17 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (CRC) and other cancers
US20180179283A1 (en) 2015-06-08 2018-06-28 Adicet Bio Inc. T cell receptor like antibodies having fine specificity
NL2014935B1 (en) 2015-06-08 2017-02-03 Applied Immune Tech Ltd T cell receptor like antibodies having fine specificity.
CA3020555A1 (en) 2016-04-08 2017-10-12 Adaptimmune Limited T cell receptors
RU2018138838A (ru) 2016-04-08 2020-05-14 Адаптимьюн Лимитед Т-клеточные рецепторы
CA3020530A1 (en) 2016-04-08 2017-10-12 Adaptimmune Limited T cell receptors
WO2018022573A1 (en) 2016-07-27 2018-02-01 Sharp Laboratories Of America, Inc. Wireless telecommuncations methods and apparatus using system information value tag
US20200325244A1 (en) 2020-05-18 2020-10-15 Abexxa Biologics, Inc. Antibodies and methods of use thereof
CN110809580A (zh) 2017-01-24 2020-02-18 安贝科思生物制剂公司 用于靶向癌症中包含非典型hla-i和新抗原的复合体的方法和组合物
CN110709516B (zh) 2017-06-05 2023-06-27 国立大学法人三重大学 识别来自mage-a4的肽的抗原结合性蛋白
BR112019028280A2 (pt) 2017-07-04 2020-07-14 Curevac Ag moléculas de ácido nucleico
JP2021500852A (ja) 2017-08-18 2021-01-14 グリットストーン オンコロジー インコーポレイテッド 共有抗原を標的にする抗原結合タンパク質
US20190201443A1 (en) 2017-09-06 2019-07-04 California Institute Of Technology Signaling and antigen-presenting bifunctional receptors (sabr)
EP3731876A4 (en) 2017-12-28 2022-04-06 Gritstone bio, Inc. ANTIGEN-BINDING PROTEINS DIRECTED AGAINST COMMON ANTIGENS
JP7469807B2 (ja) 2018-04-19 2024-04-17 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム Ｍａｇｅ－ｂ２特異性を有するｔ細胞受容体およびその使用
EP3796927A4 (en) 2018-05-23 2022-04-20 Gritstone bio, Inc. SHARED ANTIGENS
US20200291116A1 (en) 2020-05-18 2020-09-17 Abexxa Biologics, Inc. Antibodies and methods of use thereof
US20200291127A1 (en) 2020-05-18 2020-09-17 Abexxa Biologics, Inc. Antibodies and methods of use thereof
US20200291128A1 (en) 2020-05-18 2020-09-17 Abexxa Biologics, Inc. Antibodies and methods of use thereof

Also Published As

Publication number Publication date
MA49157A (fr) 2021-06-02
US20220257739A1 (en) 2022-08-18
HUE057014T2 (hu) 2022-04-28
LT3545965T (lt) 2021-09-10
MX2020011791A (es) 2020-11-24
HRP20192212T4 (hr) 2022-11-25
ES2763911T5 (es) 2023-01-05
MX2020011793A (es) 2020-12-07
KR102435015B1 (ko) 2022-08-22
PL3626731T3 (pl) 2022-05-02
CY1122491T1 (el) 2020-10-14
MA49156A (fr) 2020-03-25
CY1124813T1 (el) 2022-11-25
MD3626729T2 (ro) 2021-12-31
US20220118071A1 (en) 2022-04-21
SI3626731T1 (sl) 2021-12-31
MD3236985T3 (ro) 2023-03-31
CY1124846T1 (el) 2022-11-25
HRP20211580T1 (hr) 2022-01-21
RS62575B1 (sr) 2021-12-31
JP2020191866A (ja) 2020-12-03
TWI754892B (zh) 2022-02-11
MD3545965T2 (ro) 2021-10-31
KR20240033128A (ko) 2024-03-12
MX2020011787A (es) 2020-11-24
PT3626729T (pt) 2021-11-03
LT3626731T (lt) 2022-02-10
AU2022268329A1 (en) 2023-02-02
US20220339272A1 (en) 2022-10-27
US20220023403A1 (en) 2022-01-27
CY1124847T1 (el) 2022-11-25
CR20210289A (es) 2021-06-30
ES2887107T3 (es) 2021-12-21
PL3626729T3 (pl) 2022-02-21
LT3616706T (lt) 2022-02-10
KR102643923B1 (ko) 2024-03-05
PE20211740A1 (es) 2021-09-06
PT3616706T (pt) 2021-11-23
MA46913B1 (fr) 2021-09-30
JP7448423B2 (ja) 2024-03-12
MA48487A (fr) 2020-03-04
KR20200123269A (ko) 2020-10-28
SI3616706T1 (sl) 2021-12-31
US11559573B2 (en) 2023-01-24
MX2020004757A (es) 2020-08-20
HUE056087T2 (hu) 2022-01-28
PL3616706T3 (pl) 2022-02-07
DK3236985T4 (da) 2022-11-28
FI3236985T4 (fi) 2022-12-15
US20220023404A1 (en) 2022-01-27
MA48487B1 (fr) 2021-11-30
JP2020191865A (ja) 2020-12-03
CO2017003772A2 (es) 2017-09-20
JP2020191867A (ja) 2020-12-03
DK3236985T3 (da) 2020-01-20
JP2023100927A (ja) 2023-07-19
SG10202102698VA (en) 2021-04-29
TWI794679B (zh) 2023-03-01
ES2763911T3 (es) 2020-06-01
KR20200066382A (ko) 2020-06-09
HUE046641T2 (hu) 2020-03-30
MD3626731T2 (ro) 2022-01-31
ES2900106T3 (es) 2022-03-15
JP2020191864A (ja) 2020-12-03
LT3236985T (lt) 2019-12-27
US20220031824A1 (en) 2022-02-03
CY1124533T1 (el) 2022-07-22
US11576956B2 (en) 2023-02-14
HRP20211753T1 (hr) 2022-04-01
SG10202101444UA (en) 2021-03-30
JP7346361B2 (ja) 2023-09-19
HUE056607T2 (hu) 2022-02-28
CL2021001479A1 (es) 2022-02-04
US11672848B2 (en) 2023-06-13
MD3616706T2 (ro) 2022-01-31
PL3545965T3 (pl) 2021-12-27
US20220354939A1 (en) 2022-11-10
MA46913A (fr) 2021-03-24
MD3236985T2 (ro) 2020-02-29
ES2896919T3 (es) 2022-02-28
UA124331C2 (uk) 2021-09-01
HUE055489T2 (hu) 2021-11-29
ES2899425T3 (es) 2022-03-11
JP7026411B2 (ja) 2022-02-28
JP7358299B2 (ja) 2023-10-10
TW202321273A (zh) 2023-06-01
MX2020011794A (es) 2020-12-07
MX2020005188A (es) 2020-08-20
KR20220118565A (ko) 2022-08-25
MA49155B1 (fr) 2021-11-30
MY178137A (en) 2020-10-05
JP2020191868A (ja) 2020-12-03
MA50819A (fr) 2021-04-07
PT3545965T (pt) 2021-09-20
TW202124426A (zh) 2021-07-01
PT3626731T (pt) 2021-11-29
KR102395995B1 (ko) 2022-05-09
MA49155A (fr) 2021-04-28
TW202028231A (zh) 2020-08-01
US11679147B2 (en) 2023-06-20
JP7109801B2 (ja) 2022-08-01
ZA201701762B (en) 2018-05-30
JP2020191873A (ja) 2020-12-03
US20220054613A1 (en) 2022-02-24
US11779638B2 (en) 2023-10-10
US20230031307A1 (en) 2023-02-02
HRP20192212T1 (hr) 2020-03-20
IL281752A (en) 2021-05-31
JP2020191869A (ja) 2020-12-03
HRP20211327T1 (hr) 2022-01-21
US20220016227A1 (en) 2022-01-20
LT3626729T (lt) 2021-10-25
PT3236985T (pt) 2020-01-22

Similar Documents

Publication Publication Date Title
HRP20210698T1 (hr) Peptidi i kombinacija peptida za uporabu u imunoterapiji protiv karcinoma dojke i drugih karcinoma
HRP20201281T1 (hr) Novi peptidi i kombinacija peptida za uporabu u imunoterapiji protiv epitelnog karcinoma jajnika i drugih karcinoma
HRP20202019T1 (hr) Novi peptidi i kombinacija peptida za uporabu u imunoterapiji protiv raka jajnika i drugih malignih tumora
HRP20210709T1 (hr) Peptidi i kombinacija peptida za imunoterapiju protiv karcinoma prostate i druge vrste karcinoma
HRP20201467T1 (hr) Nova imunoterapija protiv raznih vrsta karcinoma, uključujući gastrointestinalni karcinom i gastrični karcinom
JP2020198875A5 (hr)
AR121383A2 (es) Péptidos y combinación de péptidos y andamiajes para su uso en inmunoterapia contra carcinoma de células renales (rcc) y otros cánceres
JP2020182458A5 (hr)
JP2020191862A5 (hr)
HRP20192262T1 (hr) Nova imunoterapija protiv nekoliko tumora, kao što su rak pluća, uključujući mikrocelularni karcinom pluća (nsclc)
HRP20201228T1 (hr) Nova imunoterapija protiv nekoliko tumora, uključujući tumore neurona i mozga
HRP20230512T1 (hr) Novi peptidi i kombinacija peptida za uporabu u imunoterapiji protiv karcinoma jajnika i drugih karcinoma
RU2020113032A (ru) Новые пептиды и комбинации пептидов для применения в иммунотерапии рака легких, в том числе немелкоклеточного рака легких (нмрл) и других видов рака
JP2019513005A5 (hr)
HRP20210076T1 (hr) Novi peptidi i kombinacija peptida za uporabu u imunoterapiji protiv karcinoma ezofagusa i drugih karcinoma
JP2019516663A5 (hr)
JP2021101700A5 (hr)
JP2019515650A5 (hr)
JP2011520436A5 (hr)
HRP20230878T1 (hr) Novi peptidi i kombinacija peptida za uporabu u imunoterapiji protiv raznih karcinoma (seq id 25 - mrax5-003)
JP2019520038A5 (hr)
HRP20210528T1 (hr) Novi peptidi i kombinacija peptida i njihovih skela za uporabu u imunoterapiji protiv kolorektalnog karcinoma i drugih karcinoma
JP2019536426A5 (hr)
HRP20211754T1 (hr) Novi peptidi i kombinacije peptida za upotrebu u imunoterapiji protiv hepatocelularnog karcinoma (hcc) i drugih rakova
HRP20191671T1 (hr) Nova imunoterapija za liječenje nekoliko tumora krvi, kao što je akutna mijeloidna leukemija (aml)